Please login to the form below
Linzess
This page shows the latest Linzess news and features for those working in and with pharma, biotech and healthcare.
China approves Ironwood Pharma’s IBS treatment
Coincides with AZ's Mark Mallon taking over as CEO. Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion.
Latest news
-
Shire bags US approval for constipation drug Motegrity
s Linzess and Synergy’s Trulance. ... Linzess (linaclotide) – which brought in almost $575m in sales for Allergan in the first nine months of the year – works by binding to intestinal epithelial cells and stimulating the secretion of
-
NICE backs Allergan's IBS therapy Truberzi
includes Linzess (linaclotide) for IBS with constipation. ... Viberzi sales in the US were almost $73m in the first six months of the year, almost a three-fold increase over the same period a year earlier, while Linzess contributed
-
FDA approves Synergy's constipation drug Trulance
Plecanatide's closest competitor in the market is Ironwood/Allergan's Linzess/Constella (linaclotide), described as a guanylate cyclase stimulant, which is approved for the treatment of constipation-predominant IBS in ... Allergan reported Linzess sales
-
AZ and Ironwood to file IBS drug linaclotide in China next year
Linaclotide is a guanylate cyclase‐C agonist that is already sold in the US as Linzess for IBS-C and chronic idiopathic constipation (CIC) by Ironwood and Allergan and is growing
-
Forest Labs agrees $1.46bn deal to buy Furiex
sit well in its portfolio alongside constipation-predominant IBS drug Linzess (linaclotide).
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Oral biologics delivery still elusive
years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... All eyes will now be on the performance
-
Pharma deals during April 2014
Forest is building a leading position in the $38bn gastroenterology (GI) market adding eluxadoline to its broader GI portfolio including Linzess.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Ironwood appoints Edward Owens to board
Owens is a former partner at investments advisor Wellington Management, and joins the US-based biopharma at a time of growth following the approval of Linzess (linaclotide) in the US for ... The execution of a successful launch of Linzess should provide
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- The patient voice – the value of patient-reported outcomes in HTA
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention
- GSK/Merck KGgA cancer drug fails in third trial
- Chiesi Group's Trimbow wins European licence
- Roche shares new positive Ocrevus data for MS patients
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Using behavioural psychology to improve patient recruitment
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
